Please use this identifier to cite or link to this item:
https://islhd.intersearch.com.au/islhdjspui/handle/1/5534| Title: | Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre open-label global phase 3 randomised controlled trial |
| Authors: | Sezer A Kilickap S Gümüş M Bondarenko I Özgüroğlu M Gogishvili M Turk HM Cicin I Bentsion D Gladkov O Clingan P Sriuranpong V Rizvi N Gao B Li S Lee S McGuire K Chen CI Makharadze T Paydas S Nechaeva M Seebach F Weinreich DM Yancopoulos GD Gullo G Lowy I Rietschel P. |
| ISLHD Author: | Clingan, Philip |
| Keywords: | Pharmagology;Oncology |
| Date Published: | 14-Feb-2021 |
| Citation: | Lancet. 2021 Feb 13;397(10274):592-604. doi: 10.1016/S0140-6736(21)00228-2. |
| Keywords: | Pharmagology Oncology |
| URI: | https://islhd.intersearch.com.au/islhdjspui/handle/1/5534 |
| Appears in Collections: | Research publications from current and former ISLHD staff. |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.